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A New Subtype of Brachydactyly Type B Caused by Point
Mutations in the Bone Morphogenetic Protein Antagonist
NOGGIN
K. Lehmann,* P. Seemann,* F. Silan, T. O. Goecke, S. Irgang, K. W. Kjaer, S. Kjaergaard,
M. J. Mahoney, S. Morlot, C. Reissner, B. Kerr, A. O. M. Wilkie, and S. Mundlos
Brachydactyly type B (BDB) is characterized by terminal deﬁciency of ﬁngers and toes, which is caused by heterozygous
truncating mutations in the receptor tyrosine kinase–like orphan receptor 2 (ROR2) in the majority of patients. In a
subset of ROR2-negative patients with BDB, clinically deﬁned by the additional occurrence of proximal symphalangism
and carpal synostosis, we identiﬁed six different point mutations (P35A, P35S, A36P, E48K, R167G, and P187S) in the
bone morphogenetic protein (BMP) antagonist NOGGIN (NOG). In contrast to previously described loss-of-function
mutations in NOG, which are known to cause a range of conditions associated with abnormal joint formation butwithout
BDB, the newly identiﬁed BDB mutations do not indicate a major loss of function, as suggested by calculation of free-
binding energy of the modeled NOG-GDF5 complex and functional analysis of the micromass culture system. Rather,
they presumably alter NOG’s ability to bind to BMPs and growth-differentiation factors (GDFs) in a subtle way, thus
disturbing the intricate balance of BMP signaling. The combined features observed in this phenotypic subtype of BDB
argue for a functional connection between BMP and ROR2 signaling and support previous ﬁndings of a modulating
effect of ROR2 on the BMP-receptor pathway through the formation of a heteromeric complex of the receptors at the
cell surface.
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Brachydactyly is shortness of the ﬁngers and/or toes
(digits), usually inherited as a dominant trait. Itmost often
occurs as an isolated physical feature but can also be part
of a more complex set of anomalies such as a skeletal
dysplasia or a congenital malformation syndrome. Accord-
ing to their pattern of skeletal hand malformation, the
different isolated brachydactylies have been classiﬁed into
the subtypes A–E.1 Brachydactyly type B (BDB), the most
severe form, is characterized by aplasia or hypoplasia of
the distal andmiddle phalanges of digits II–V. In less severe
cases, hypoplasia of the distal phalanx is associated with
hypoplasia of the nails and fusion of distal interphalangeal
joints. To date, heterozygous mutations in the gene en-
coding the receptor tyrosine kinase–like orphan receptor
2 (ROR2 [GenBank accession number NM_004560]) have
been reported to be the cause of BDB1 (MIM 113000) in
the majority of affected individuals. Thesemutations clus-
ter in two regions, resulting in truncation of the receptor
of either the N-terminal or C-terminal of the intracellular
tyrosine kinase domain.2,3
The patients described here were screened formutations
in ROR2, but no mutations were identiﬁed. ROR2-nega-
tive BDB has been described before, indicating genetic
heterogeneity of the disorder, but the molecular basis in
this group of patients was not known. Previous studies
have shown that BMPR1B, the high-afﬁnity receptor for
GDF5, interacts with ROR2.4 We therefore sequenced
GDF5, BMPR1B, and the inhibitor of GDF5—NOGGIN
(NOG [GenBank accession number NM_005450])—in all
ROR2-negative subjects. Informed consent for genetic an-
alyses was obtained from all patients or their legal guard-
ians. Molecular testing was performed on puriﬁed genomic
DNA obtained from venous blood samples. The primer
sequences and PCR conditions for the molecular testing
can be found elsewhere (for ROR2,3 for GDF5,5 and for
BMPR1B6). The NOG-coding region was ampliﬁed in two
overlapping segments, with use of the following primer
pairs: 1-1 forward (5′-CTCGGCGTGCTCTCCTC-3′) and 1-
1 reverse (5′-GCTTAGGCGCTGCTTCTTG-3′), which pro-
duced a PCR product of 476 bp, and 1-2 forward (5′-ACCT-
GGCGGAGCTGGAC-3′) and 1-2 reverse (5′-GAACTGGTT-
GGAGGCGG-3′), which produced a PCR product of 479
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Figure 1. Pedigrees of families with identiﬁed NOG mutations, as indicated. Affected persons are indicated by blackened symbols.
Symbols with horizontal lines indicate individuals for whom mutation analysis was performed.
bp. PCR conditions can be obtained on request. Sequenc-
ing was done using the ABI Prism BigDye Terminator Se-
quencing Kit (Applied Biosystems), with PCR primers used
as sequencing primers. Products were evaluated on an au-
tomated capillary sequencer (Applied Biosystems).
We discovered heterozygosity for ﬁve differentmissense
mutations in NOG in six familial cases (c.103CrG [P35A],
c.103CrT [P35S], c.106GrC [A36P], c.142GrA [E48K],
and c.559 CrT [P187S]), originating from Germany, Tur-
key, Denmark, Iran, and the United Kingdom. In one pa-
tient from North America, a de novo mutation, c.499CrG
(R167G), conﬁrmed bymolecular testing in the unaffected
parents, was detected. Heterozygous mutations in NOG
have been reported elsewhere to be associated with several
human disorders characterized by abnormal joints, in-
cluding proximal symphalangism (SYM1 [MIM 185800]),
tarsal-carpal coalition syndrome (TCC [MIM 186570]),
multiple synostosis syndrome (SYNS1 [MIM186500]), and
stapes ankylosis with broad thumb and toes without sym-
phalangism (MIM 184460).7–10
In ﬁve of the six families, DNA samples from additional
family members were available for NOG screening. Se-
quence analysis demonstrated that the NOG mutations
segregated with the phenotype with an autosomal dom-
inant inheritance in a total of 24 meioses (ﬁg. 1). All pa-
tients exhibited a distinct clinical phenotype, featuring
absent/hypoplastic terminal and/or middle phalanges with
an amputation-like phenotype similar to that observed in
BDB (ﬁg. 2A). In most patients, ﬁngers IV and V showed
a severe transverse distal reduction, and ﬁngers II and III
were less severely affected. In those ﬁngers in which the
distal phalanges were present, abnormal proximal inter-
phalangeal joints were observed, which resulted in the in-
ability to bend the ﬁngers and in missing ﬂexion creases.
The most severely affected patients showed a BDB phe-
notype, with an entire aplasia of the distal and middle
phalanges of digits II–V. A few of the patients had amilder
phenotype, featuring hypoplastic distal phalanges II–V.
We categorized the phenotypic expression observed in the
patients’ hands into three groups: mild (distal phalanges
of ﬁngers II-V present but hypoplastic); intermediate (ab-
sent distal and sometimes middle phalanges of ulnar rays
[ﬁngers IV and V more severely affected than ﬁngers II
and III]), and severe (distal and sometimes middle pha-
langes of ﬁngers II–V absent) (table 1).
In those individuals in whom ﬁngers II–V consisted of
two or three phalanges, a fusion of the proximal inter-
phalangeal joints (SYM1) was typically present. Fusion of
the distal interphalangeal joints (distal symphalangism
[SYM]), similar to ﬁngers observed in patients with ROR2
mutations associated with a mild phenotype, was addi-
tionally observed in patients showing a mild BDB who
carried an E48K or a P187S NOG mutation. The available
radiographs of the adult patients’ hands and feet veriﬁed
the phalangeal joint fusions. In addition, they revealed a
coalition of carpal and tarsal bones leading in the hands
to a small metacarpus with abnormally conﬁgured bones.
In two children, we observed an acceleration of bone age.
In a newborn girl, an accelerated development of carpal
bones of ∼6 mo was present (radiographs not shown). In
a 6-mo-old child, the status of carpal bones corresponded
to the development of a 3-year-old child (ﬁg. 2B [mag-
niﬁcation in ﬁg. 2c]). In the latter case, the distance be-
tween the hamate and the triquetral bones was narrowed,
indicating a future fusion of those two bones, and the
proximal epiphysis of metacarpal bone I was unusually
formed, caused by an accelerated ossiﬁcation. The thumbs
were proximally set in the majority of patients, because
of short ﬁrstmetacarpal bones. Cutaneous syndactyly, par-
ticularly between ﬁngers II and III and between ﬁngers III
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Figure 2. Clinical phenotypes caused by the NOG mutations. In panel A, pictures in each vertical group belong to one patient;
corresponding mutations are depicted above. In hands, note variable terminal deﬁciency of ﬁngers. Terminal deﬁciency—particularly
of phalanges IV and V, with a milder involvement of distal phalanges II and III (“intermediate” BDB in table 1)—are depicted in
patients 1, 2, 4, and 6. Severely affected hands with absent distal and middle phalanges of ﬁngers II–V (“severe” BDB in table 1) are
shown in patient 3. Hypoplastic but present distal phalanges of ﬁngers (“mild” BDB in table 1) are shown in patient 5. Note proximally
set thumbs and additional cutaneous syndactyly in some affected hands. Radiographs show proximal SYM of ﬁngers II–V, present in
ﬁngers consisting of at least two phalanges. Fusion of carpal bones is a further typical feature (in patient 1, note the atypically
conﬁgured carpal bones with fusion of hamate, capitate, trapezoid, and trapezium). Shortened metacarpal bones I can be seen in most
affected hands. In feet, toes are similarly affected (patient 6 had surgical removal of toes). B, Magniﬁcations. a, Proximal SYM. b,
Proximal and distal SYM, as observed in patient 5. c, Accelerated development of carpal bones and the proximal epiphysis of metacarpal
bone I in a 6-mo-old child. Note narrowed distance between hamate and triquetrum, indicating a future fusion. d, Absent ﬂexion
creases due to the fused interphalangeal joints. e, Symmetric constriction rings in the middle of both second toes in patient 2, imitating
a condition caused by amniotic bands.
and IV, was observed as an associated feature. The patients’
feet were affected in a similar way. Toes II–V showed ter-
minal deﬁciency to a variable degree, and they were stiff-
ened if they consisted of more than one phalanx. The big
toes appeared normal. Interestingly, we observed symmet-
ric constrictions in the middle of both second toes in one
of the described patients (ﬁg. 2B [magniﬁcation in ﬁg. 2e]).
This phenotype imitates a condition typically caused by
amniotic bands. Sensorineural hearing loss and farsight-
edness were observed in a few patients. The overall clini-
cal manifestations of the investigated patients are sum-
marized in table 1.
Our clinical data describe a new subtype of brachydac-
tyly characterized by hypoplasia/aplasia of distal phalan-
ges in combination with (1) SYM, (2) fusion of carpal/
tarsal bones, and (3) partial cutaneous syndactyly.We pro-
pose to call this type of hand/foot malformation “brach-
ydactyly type B2” (BDB2), because of its striking similarity
to BDB1. A clinical description of a family published by
Herrmann11 and some of the patients reported by Maro-
teaux et al.12 seem to have a comparable phenotype, with
variable brachydactyly and associated joint fusions.
We excluded a NOG mutation in BDB-affected family 3
described by Oldridge et al.13 in 1999; the family was also
negative for mutations in ROR2, indicating that at least
one further locus for BDB exists.
In the patients presented here, the P35S mutation in
NOG was identiﬁed in two unrelated individuals, whereas
each of the changes P35A, A36P, E48K, R167G, and P187S
was detected once. The mutation R167G occurred de novo.
All detected changes cosegregate with the BDB2 pheno-
type, affect highly conserved amino acids of NOG (data
not shown), are not present in 200 control individuals,
and are thus likely to represent pathogenic mutations.
Overall, we identiﬁed six different NOG mutations. The
mutations altering codons 36, 167, and 187 are novel,
whereas NOG mutations affecting codons 35 and 48 have
been described elsewhere in association with abnormal
joint fusions in hands and feet.7,8,14 In a woman carrying
the same E48K mutation, an association of premature
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P35A 2/12 10/12 8/8 8/8 8/8
P35S 3/6 3/6 5/5e 5/5 4/6
A36P 4/4 2/2 0/2 0/4
E48K 2/4 2/4  2/2 2/2 0/4
R167G 2/2 1/2f 0/2 0/2
P187S 3/6 3/6  2/2 1/2g 6/6
NOTE.—All subjects had proximal SYM. Each hand of the patients was counted separately.
Radiographs were not available for all affected individuals. For each of the listed features, the
observed phenotypes refer to the total number of available data (as indicated after the slash).
a Distal phalanges and nails present, but hypoplastic in ﬁngers II–V.
b Absent distal and sometimes middle phalanges of ﬁngers IV and/or V (more affected by
BDB than are ﬁngers II and III).
c Absent distal (and middle) phalanges of ﬁngers II–V.
d MC Ipmetacarpal bone I.
e Two of ﬁve are x-rays of a 6-mo-old child; both hands showed an accelerated carpal bone
age of ∼2.5 years.
f In x-rays of a newborn, both hands showed an accelerated carpal bone age of ∼6 mo.
g Additionally shortened MC IV and V.
ovarian failure, proximal and distal SYM, TCC, and short-
ness of single ﬁngers and toes with hypoplastic ﬁngernails
was reported.14 The P35S change is listed as a SNP, but
screening of 200 control individuals did not show any
alteration at codon 35 in NOG. Furthermore, the P35S
mutation was identiﬁed in an Italian family with SYM1.15
In the clinical description of an affected father and son,
additional hypoplasia of distal phalanges was mentioned.
Another mutation at position 35, a change from proline
to arginine (P35R), described twice elsewhere, resulted ei-
ther in isolated SYM1 or in TCC.7,8 These data support an
essential function of the amino acid P35 in NOG.
NOG is an extracellular antagonist of bone morpho-
genetic proteins (BMPs) and growth-differentiationfactors
(GDFs). The BMP family of secreted molecules has mul-
tiple roles in early embryonal development and particu-
larly in skeletogenesis. BMPs and GDFs promote the pro-
liferation and differentiation of mesenchymal precursor
cells into chondrocytes and/or osteoblasts and initiate and
control the formation of joints at speciﬁc regions.16 GDF5
plays an essential role in chondrocyte differentiation and
in the ﬁne tuning of phalangeal development.17,18 This
complex regulation of BMP andGDF activity is speciﬁcally
modulated by inhibition through the presence of several
BMP antagonists, like NOG.19,20
The proteins of the BMP family exert their effect via two
different types of BMP receptors: the type I (BMPR1B and
BMPR1A) and the type II receptors. The afﬁnities of ligands
toward the BMP receptors differ. For example, GDF5 binds
with a high afﬁnity to BMPR1B, whereas BMP2 can bind
to both BMPR1A and BMPR1B. After ligand binding, the
BMP type I receptors get activated through the BMP type
II receptor by a phosphorylation process leading to in-
tracellular downstream signaling of SMAD (homolog of
mothers against decapentaplegic, Drosophila) proteins and
the MAP (mitogen-activated protein) kinase pathway.21,22
NOG binds to BMPs and thereby masks the BMP type I and
II receptor–binding sites of certain BMPs andGDF5,23,24and,
subsequently, no signaling is initiated.25–27
To elucidate the possible molecular mechanisms by
which these newly identiﬁed mutations in NOG may act
to produce BDB in combination with joint fusions, we
superimposed the altered amino acid residues on the
known three-dimensional structure of human NOG (ﬁg.
3). The structure of the complex has been modeled by
alignment of the sequence of human GDF5 on the Protein
Data Bank (PDB) coordinates of the BMP7 dimer within
the NOG:BMP7 structure (PDB entry 1M4U), which was
solved by x-ray crystallography.24,28 The type I and II re-
ceptor–binding sites have been determined usingPP_SITE.29
The estimated reduction of free-binding energy was cal-
culated for each NOG mutant by FOLD-X.29,30 The free-
binding energy of the complex formation of wild-type
(WT) NOG and GDF5 was calculated and set to 100% (ta-
ble 2). The comparison of the free-binding energy of WT
NOG versus the NOG mutants to GDF5 shows that the
mutation P35R, which is known to be associated with
SYM1 or TCC (but not BDB), has the highest loss of free-
binding energy (51%). The BDB2-associated mutations
showed a less severe reduction in free-binding energy. The
mutations P35A resulted in 14% and P35S in 31% relative
loss of free-binding energy; the mutation P187S resulted
in 16% loss of free-binding energy. The remainder of
BDB2-related mutations at positions A36, E48, and R167
led to reductions of !6%. Thus, the behavior of the ma-
jority of BDB2 mutations is similar to that of WT NOG,
and BDB2 mutations are able to antagonize GDF5 func-
392 The American Journal of Human Genetics Volume 81 August 2007 www.ajhg.org
Figure 3. Three-dimensional model of NOG-GDF5 complex highlighting altered NOG amino acids found in patients with BDB2. NOG is
depicted in a ribbon structure, with one monomer in dark and the second in light pink. GDF5 is shown as a surface model, with one
monomer in dark and the second in light gray. Amino acids of GDF5 that interact with BMP receptor type I are highlighted in dark and
light orange, and amino acids that interact with BMP receptor type II are highlighted in dark and light green. The binding of NOG to
BMPs/GDFs blocks both receptor-binding sites. NOG mutations identiﬁed in patients with BDB2 are indicated. They affect three different
structural clusters: (1) the site that covers the type I receptor pocket in BMPs/GDFs (P35 and A36 [red]) (2) the site that covers the
type II receptor pocket (E48 and R167 [yellow]), and (3) the NOG-dimerization site (P187 [blue]).
tion. Our data indicate that a loss ofNOG-GDF5 inhibition
is not sufﬁcient to explain the BDB2 phenotype.
Interestingly, the identiﬁed BDB2-associated mutations
in NOG do not cluster on a certain domain; rather, they
affect three independent regions: (1) the dimerization do-
main (P187, marked in blue in ﬁg. 3), (2) the site that
covers the type I receptor pocket in BMPs/GDFs (P35 and
A36, marked in red in ﬁg. 3), and (3) the site that covers
the type II receptor pocket (E48 and R167, marked in yel-
low in ﬁg. 3).
NOG and GDF5 are dimers linked by a disulﬁde bridge.
The C-terminal region of NOG contains a cysteine-knot
motif of nine cysteine residues that is important for di-
sulﬁde-bond formation and dimerization.24 One of the
BDB2-causing NOG mutations (P187S) lies in the critical
dimerization interface of NOG. This alteration destabilizes
the NOG-homodimer binding, possibly inﬂuencing the
overall structural integrity of the NOG-BMP complex for-
mation. This was conﬁrmed by western-blot analysis of
supernatants of DF-1 cells expressing WT Nog or mutant
variants. For the expression of Nog mutants, replication-
competent avian sarcoma (RCAS) viruses containing the
coding sequence of chicken Nog (kind gift from A. Vort-
kamp) were digested with ClaI and were cloned into p-
SLAX-13. This construct was used for introduction of mu-
tations into the chicken sequence of Nog corresponding
to the human mutations P35A, P35R, P35S, A36P, R167G,
and P187S, with use of theQuickChange Site-DirectedMu-
tagenesis Kit (Stratagene) according to the manufacturer’s
recommendations. The coding sequence of all constructs
was digested with ClaI and was cloned into the viral vector
RCASBP-B. Production and concentration of viral particles
were performed as described elsewhere.31 Concentrated vi-
ruses of WT Nog and mutants were used to infect DF-1
cells. After cells reached conﬂuence, the growth medium
was substituted with Dulbecco’s modiﬁed Eagle medium
(DMEM) without fetal calf serum, and the supernatantwas
collected the next day. Proteins were precipitated over-
night with acetone. Acetone was removed after centrifu-
gation, and the pellet was resuspended in loading buffer
for nonreducing conditions (200 mM Tris-HCl [pH 7.5],
4% SDS, 0.04% Bromophenol blue, and 40% glycerine) and
reducing conditions (nonreducing buffer with 125 mM
mercaptoethanol). Proteins were separated on an SDS/12%/
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Table 2. Calculated Changes of Free











WT Nog 42.00 100 0
SYM1/TCC:
P35R 20.70 49 51
BDB2:
P35A 36.00 86 14
P35S 29.00 69 31
A36P 41.20 98 2
E48K 41.55 99 1
R167G 39.30 94 6
P187S 35.10 84 16
NOTE.—Free-binding energy (dG) was calculated
for binding of WT NOG or indicated NOG mutants to
WT GDF5 by FOLD-X. Binding of WT NOG to WT GDF5
was set to 100% and was used as a reference for
the calculated reduction of binding energy (ddG) of
the NOG mutations. The SYM1/TCC (without BDB2)–
associated mutation P35R resulted in the highest loss
of free-binding energy (51%). In comparison, all
BDB2-associated mutations showed less reduction of
free-binding energy (1%–31%).
PAGE and were electroblotted onto an Immobilon-P
Transfer Membrane (Millipore). Immunodetection was
performed after blocking with 5% milk in PBS containing
0.2% Tween-20 with an anti-Noggin polyclonal antibody
(Santa Cruz Biotechnology [catalog number sc-25656; lot
number F2804]) and a secondary anti-rabbit–HRP anti-
body (Calbiochem [catalog number DC03L]). Signals were
detected by enhanced chemiluminescence reaction (Roth)
and exposure on light-sensitive ﬁlms.
The P187S mutation causes a disturbance of Nog dimer-
ization that leads to the secretion of monomeric forms.
In contrast, WT Nog and the other tested Nog mutants
P35R, P35S, P35A, A36P, and R167G are properly secreted
as disulﬁde-bonded dimers (ﬁg. 4A and 4B). We hypoth-
esize that the mutation P187S interferes with the forma-
tion of an intermolecular disulﬁde bridge, thus disturbing
the formation of two Nog molecules to a dimer without
leading to a severe conformational change of monomeric
Nog. It is possible that two mutant monomers are still
able to inhibit BMPs by assembling to a dimerlike structure
with antagonistic properties when binding to BMPs. This
possibility is supported by the observation that overex-
pression of the P187S Nog mutant in the micromass cul-
ture system leads to an inhibition of endogenous chon-
drogenesis comparable to WT Nog (ﬁg. 4C).
The NOG-GDF5 complex is assembled mainly by two
hydrophobic areas. NOG is predicted to bind toGDFs/BMPs
in a two-step mechanism. First, NOG supposedly binds the
BMP receptor type II interface of BMPs, upon which the
N-terminal region hinges toward the BMP receptor type I
interface. Amino acids 35 and 36 are located in one of
the hydrophobic regions, the so-called NOG clip domain,
spanning amino acids 28–39. This region inserts through
hydrophobic interactions in the hydrophobic pocket of
BMPs, thus blocking the BMP binding site for the BMP
type I receptors, as depicted in ﬁgure 3. A key function at
this site can be predicted for amino acid P35. With its hy-
drophobic ring, proline forms a direct contact to this BMP
pocket.24 It is highly probable that amino acid changes at
this position lead to a conformational change of the N-
terminal hydrophobic NOG region and therefore are likely
to disturb the afﬁnity and speciﬁcity toward certain BMPs/
GDFs. An amino acid change substituting the hydropho-
bic proline for a polar, hydrophilic serine (P35S), as in two
of the investigated families, is expected to induce a steric
hindrance, because serine will not ﬁt into the hydropho-
bic BMP pocket. In the case of the SYM1/TCC–associated
P35R mutation, this effect can be expected to be more
dramatic, possibly explaining the different phenotypic
outcome.
The NOG region, amino acids 40–48, forms another hy-
drophobic interaction domain that is predicted to mask
the interaction site of BMPs that binds to the BMP type
II receptors. The mutation E48K, an amino acid change
from glutamic acid to basic lysine, is likely to interfere with
binding at this site. The amino acid substitution R167G,
a change from hydrophobic arginine to a small uncharged
glycine, is also located in a ﬁnger domain located close to
this BMP receptor II site. Bothmutations are likely to result
in free BMP type II receptor–binding sites, possibly leading
to increased binding of BMPs to their type II receptors
and a shift toward the BMP type II receptor, because the
BMPR1A/B sites are still covered by NOG. The effect of
this situation on BMP signaling is not entirely clear. So
far, it is known that a heterodimer formation between the
type I and II receptors is a necessary initial step for signal
transduction in chondrogenesis. This may still be pre-
vented by binding of mutated NOG to the type I receptor
site, thus inhibiting chondrogenic differentiation, as ob-
served in the micromass system.
Taken together, our current data show that most of the
identiﬁed mutations are clustered in regions of the NOG
protein that block the BMP-binding sites for the BMP re-
ceptors. This is likely to result in an enhanced or altered
signaling via the BMP receptors. The importance of BMP
receptors for limb development is exempliﬁed by overex-
pression studies in the chick,32 gene inactivation experi-
ments in the mouse,33 and the identiﬁcation of muta-
tions in human limb-malformation syndromes.6,34,35 A dis-
equilibrium of BMP receptor signaling caused by an al-
tered NOG protein is likely to result in a disturbance of
phalangeal development. This effect must be different
from NOG loss-of-function mutations, observed in SYM1,
since distal aplasia of phalanges is not observed in these
patients.
For functional analyses of the BDB-associated NOG mu-
tations, we overexpressed them by an RCAS retrovirus
in the chicken limb-bud micromass culture system as de-
scribed elsewhere.6 When cells were seeded, 1 ml of con-
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Figure 4. Secretion of Nog mutant proteins by DF-1 cells and functional analysis in the micromass culture system, with western-blot
analysis of conditioned media from DF-1 cells infected with RCASBP-B containing the coding sequence of either Nog WT sequence (WT
Nog), BDB-associated mutant sequence (P35A, P35S, A36P, R167G, and P187S), or SYM1/TCC–derived sequence (P35R). As a negative
control, DF-1 cells were infected with empty RCASBP-B (control). A, SDS-PAGE under nonreducing conditions and immunodetection with
use of anti-Nog antibody. WT Nog is secreted as a disulﬁde-bonded dimer, as are mutants P35A, P35R, P35S, A36P, and R167G. The
mutant P187S is secreted predominantly as a monomer, and only a small amount of disulﬁde-bonded dimer is secreted, which supports
the hypothesis that this amino acid change directly affects the dimerization of Nog. B, SDS-PAGE under reducing conditions and
immunodetection with use of anti-Nog antibody. All Nog dimers resolve to monomers. C, WT Nog or indicated mutants, retrovirally
overexpressed in micromass cultures from chicken limb buds and grown for 6 d in culture medium. Chondrogenic differentiation of the
cultures was quantiﬁed by histomorphometric analysis of Alcian blue–stained nodules. WT Nog completely inhibited nodule formation
in the micromass cultures. The inhibition of chondrogenesis by WT Nog was set to 100%. In comparison with WT Nog, the analyzed
BDB2-associated Nog mutants resulted only in a minor reduction of Nog activity. P35A, A36P, and P187S showed nearly full activity,
whereas P35S and R167G showed a reduction of 20%–25%. In contrast, the SYM1/TCC–associated Nog mutant P35R showed an obvious
reduction of ∼60% biological activity, indicating a major loss of function. D, Photographs of Alcian blue–stained micromass cultures.
centrated RCAS virus containing either WT Nog or mutant
Nog was added per culture; uninfected cultures served as
a control. For each condition, four replicates were per-
formed in parallel. Culture medium (DMEM-F12, 10% fe-
tal calf serum, and 0.2% chicken serum) was replaced ev-
ery 2–3 d. After 6 d, micromass cultures were ﬁxed and
stained with Alcian blue. Nodule formationwas quantiﬁed
by histomorphometric analysis with the software tool Aut-
mess (Zeiss) (ﬁg. 4C and 4D). As expected, WT Nog com-
pletely prevented chondrogenic differentiation, whereas
the SYM1/TCC–associated mutation P35R showed a de-
creased inhibitory activity resulting in an almost unaltered
chondrogenic differentiation. In contrast, the BDB2-asso-
ciated NOG mutants showed no major loss of biological
activity in this assay. Interestingly, this also holds true for
the P187S mutant, which was shown to be mainly mono-
meric. On the basis of these results, we conclude that the
BDB2-associated mutations do not cause a simple loss of
function and thus act in a different manner, probably by
disturbing the intricate balance of BMP signaling in amore
subtle way. Speciﬁc effects on certain BMPs or a yet-un-
known interaction to other proteins are further possible
explanations.
Even though the precise mechanisms of the pathogenic
effect caused by the NOG point mutations described here
are unclear, it is likely that BDB2 is a result of speciﬁcNOG
mutations. The observed phenotype of variable BDB in
combination with SYM1/TCC was a consistent feature in
all of the affected individuals described here. The presence
of BDB is an additional feature that distinguishes this con-
dition from other known NOG joint-fusion syndromes.
The occurrence of SYM and TCC caused by mutations
in the BMP-inhibitor NOG can possibly be explained by
a partial loss of NOG function leading to reduced binding
afﬁnity of NOG to different BMPs/GDFs.24 This might,
among other effects, result in an increased GDF5 signaling
causing abnormal joint formation. Thismechanism is sup-
ported by the observation that gain-of-functionmutations
in GDF5 may cause SYM1 or SYNS1, most likely through
the activation of BMPR1A, the receptor normally activated
by BMP2.36,37
Distal hypoplasia/aplasia of phalanges is associatedwith
truncating ROR2mutations, but how these exert their path-
ogenic effect is still unknown.2,38,39 A direct interaction be-
tween the BMP type IB receptor (BMPR1B) and ROR2 has
been demonstrated elsewhere.4 ROR2 and BMBR1B form a
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ligand-independent heteromeric complex at the cell sur-
face, leading to an activation of ROR2 through transphos-
phorylation by BMPR1B. An activated tyrosine kinase of
ROR2 was shown to inhibit the BMPR1B pathway. It was
suggested that signal transduction via both receptors is
needed for proper chondrogenic differentiation. The clin-
ical phenotype of combined BDB, SYM1, and TCC in the
patients described here supports the hypothesis of a func-
tional connection between the BMP receptors and ROR2.
In addition, the observation that a NOG mutation at the
BMP type II receptor binding site leads to distal SYM, a
feature associated with ROR2 mutations, argues for amod-
ulating effect between the two receptors. Furthermore, pa-
tients with BDB1 can be affected by fusion of carpal bones
similar to that of BDB2-affected patients with NOG mu-
tations.3 The occurrence of distal SYM together with SYM1
and TCC caused by mutations at the BMP type II receptor
binding site of NOG was observed elsewhere and conﬁrms
that distal interphalangeal joint fusion is not a coinciden-
tal feature.14,40 The phenotypic overlap between BDB1 and
BDB2 indicates a functional connection between BMP and
ROR2 signaling in vivo.
In summary, this work describes a new subtype of brach-
ydactyly (BDB2) due to novel mutations in NOG. This pa-
tient group is deﬁned by the presence of hypoplasia/apla-
sia of distal phalanges in combination with joint fusions.
Patients with an amputation-like phenotype should have
a thorough clinical and radiological evaluation of their
hands and feet, to identify additional SYM and carpal or
tarsal synostosis. If these joint fusions are present, a caus-
ative NOG mutation is very likely.
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